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F
rauke Melchior vividly remem-
bers the afternoon when, as a 
postdoc in Larry Gerace’s labo-
ratory, she developed the fi  lm from a 
particular experiment. It proved that her 
hypothesis was correct. The mysterious 
mobility shifts she’d observed in earlier 
experiments were due to a novel protein 
modifi   cation: addition of the peptide 
she would name “small ubiquitin-related 
modifi  er” (SUMO) (1).
Before that day in the darkroom, 
Melchior had been searching for a research 
home. Her graduate work in Marburg, 
Germany with Helmut Kindl had given 
her a solid grounding in biochemistry, 
while a two-year stint as a postdoc 
with Volker Gerke in Göttingen, Ger-
many had opened doors to molecular 
cell biology and gotten her interested 
in nuclear-cytoplasmic transport (2). 
This interest took her to 
Gerace’s laboratory at the 
Scripps Research Institute 
in San Diego, CA, where 
she helped identify the 
GTPase Ran as a critical 
player in nuclear transport 
(3). It was in the course of 
these studies that she dis-
covered SUMOylation.
Since then, Melchior has been on 
a quest to understand how and under 
what circumstances the SUMO peptide 
is added to its protein targets (4), and 
to explore the regulation and functional 
consequences of this modifi  cation  (5). 
Now in Heidelberg (having returned to 
Germany after her postdoc), she spoke 
with us about how she got into the ring 
with SUMO, and her efforts to pin its 
function to the mat.
BEST LAID PLANS
What ﬁ  rst got you interested in science?
My father was a physicist, and my 
mother had also wanted to become a 
scientist. She ended up being a chemistry 
teacher, though, because she had three 
young children and at that time, science 
wasn’t a realistic option for her. So 
when I showed an interest in science, 
my family was very supportive. I decided 
to study chemistry at University, and 
eventually stumbled into biochemistry. 
I didn’t really like it at fi  rst, but then I 
went to Helmut Kindl’s laboratory to 
complete my research requirement. I had 
a lot of fun in his laboratory, and in the 
end decided to do my master’s and PhD 
thesis there.
I love the puzzle-solving aspect of 
research—you could have put me on any 
subject. It just happened to be biochem-
istry that caught my attention fi  rst.
Did you have a plan for what you wanted 
to do after your PhD?
I’d planned to study plant biochemistry as 
a postdoc in the US. But then I became 
pregnant during my PhD. I 
had always wanted to have 
children, and in hindsight 
this turned out to be the best 
possible timing. But, my 
signifi   cant other, Ludger 
Hengst, had just started his 
PhD in Göttingen. I was two 
years ahead of him in my 
career, but we wanted to go 
to the States for our postdocs together. So, 
I joined Volker Gerke’s laboratory in 
Göttingen as a postdoc for two years to 
match our timelines together.
Why did you want to go to the States, 
and San Diego in particular?
Ludger and I considered it a fantastic 
opportunity to get to know a different 
culture, and we were looking for a place 
where there was a really high density of 
research laboratories so that we could 
both fi  nd our perfect postdoc positions. 
In Volker’s laboratory, I had worked on 
a project to identify annexins in fi  ssion 
yeast. It turns out that there aren’t any 
but I encountered a protein in my screens, 
called RNA1, that interested me. Its 
function was unclear, but there were 
links in the literature to RNA processing 
and RNA nuclear export, so I started to 
read about nuclear-cytoplasmic transport. 
It was a really young fi  eld at that time—
not a lot of work had been done at the 
molecular level. But Larry Gerace’s 
laboratory at Scripps had just published 
a paper on a new in vitro transport assay. 
I decided to go there, and it turned out 
to be the best choice I could have made. 
Larry was a very supportive and gener-
ous advisor.
BY COINCIDENCE
How did you wind up working on Ran?
Larry’s laboratory had made the initial 
observation that GTPS inhibited trans-
port in their assay. On Larry’s suggestion, 
I wrote my postdoctoral fellowship on 
this and followed up this result. I was able 
to identify that the GTPase Ran was in-
volved in transport. Coincidentally, Ludger 
had written his postdoctoral fellowship 
application on analyzing the role of Ran 
in cell cycle control in yeast. He ended up 
working on p27 instead, but if you com-
bine the postdoctoral fellowship applica-
tions that we sent to the German Research 
Society, we had it all in there—just not in 
the same proposal!
How did these studies lead you to ﬁ  nd 
SUMO?
The next logical step after fi  nding the 
GTPase was to ask where and how GTP 
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coincidence, it turns out that RNA1, which 
I had fi  rst encountered in Volker’s labora-
tory, was actually the RanGAP. So I went 
back to the RanGAP, but this time in mam-
malian cells. We were the fi   rst ones to 
make good antibodies to RanGAP, and that 
allowed us to discover that there are two 
forms in mammalian cells: one that mi-
grated at the expected size on a gel and an-
other one that migrated 20 kD larger. We 
discovered that this larger band contained 
the published sequence of RanGAP, plus a 
few novel peptides. The only 
thing similar to these pep-
tides in a BLAST search was 
ubiquitin. The similarity was 
only 18%—something that 
you'd normally consider gar-
bage—but we couldn’t fi  nd 
any other matches. We won-
dered if this might be a mod-
ifi   cation like ubiquitin. We 
had recombinant RanGAP, 
so I did probably the luckiest 
experiment in my life: we 
mixed it with HeLa cell 
extract and ATP and ran a Western blot to 
see whether the recombinant RanGAP 
would change its size. That was a moment 
that I will never forget, when the fi  lm 
came out of the developer and I saw that 
this crazy idea was correct: we’d con-
verted the 70-kD form to the 90-kD form. 
It was clear that we’d discovered a new 
protein modifi  cation.
Why do you say that was a lucky 
experiment?
Others had found the SUMO gene 
and protein before us, but the only 
people who had the chance to dis-
cover that it's a modifi  er were basi-
cally the people who happened to 
work on RanGAP. SUMO modifi  -
cation is removed by isopeptidases 
and is very unstable on most pro-
teins. RanGAP is the one protein 
that remains modifi   ed by SUMO 
when you lyse cells 
in the absence of isopepti-
dase inhibitors. I don't 
know how many laborato-
ries saw some strong, inex-
plicable band in a gel, but 
when they tried to catch 
these bands they were 
gone. Two other laborato-
ries discovered SUMOyla-
tion around the same time 
as us, and they were both 
working on RanGAP, too.
SUMO MUSE
What roles does SUMO perform in cells?
The best analogy would be phosphor-
ylation. Phosphorylation can either 
help to create a binding module that 
can be recognized by specialized pro-
tein domains, or it can block an interac-
tion surface. In the same way, SUMO 
can add binding interfaces or remove 
them. There’s also 
an example where 
SUMOylation leads 
to a conformational 
change of the mod-
ifi  ed protein. For a 
long time people 
assumed that SUMO 
protects proteins 
from ubiquitination, 
but that has turned 
out not to be true. 
It’s really hard to 
predict what SUMO 
modifi  cation will do 
to a given protein 
without looking at 
every possibility.
Where are you headed with SUMO now?
We are still very interested in basic mecha-
nisms. We are spending a lot of time charac-
terizing a SUMO E3 ligase called RanBP2, 
which is a nuclear pore complex protein that 
binds to SUMOylated RanGAP. This is a 
fascinating project because it has linked 
SUMOylation to the nuclear pore, to nu-
clear transport and the RanGTPase cycle. 
But I’m convinced that there are more 
enzymes that regulate SUMOylation—
either positively by being E3 ligases or 
negatively by being isopeptidases—that 
have yet to be identifi  ed. So we are looking 
for additional enzymes. Related to that, 
we have another project that personally I 
fi  nd very interesting, on the regulation of 
SUMOylation by reactive oxygen species. 
All kinds of stresses—like heat shock, or 
oxidative stress—lead to global changes 
in SUMOylation. We think this is because 
SUMOylation might serve to integrate and 
coordinate many different processes simul-
taneously in response to stress. This 
might be coordinated at the level of 
SUMO regulatory enzymes.
One of the great things about work-
ing on SUMO is that it takes you into all 
corners of the cell. This makes going to 
meetings a lot of fun, and also makes it 
easy to give postdocs a project that they 
can develop into their own independent 
research direction.
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Melchior (second from left) and colleagues are led to new places by 
SUMO—in this case, up a mountain in Banff, Canada.
“One of the 
great things 
about working 
on SUMO is 
that it takes 
you into all 
corners of 
the cell.”
Melchior and students discuss a new result.
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